B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
SOPH
SOPHiA GENETICSDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$6.80
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+43.3
Score
AI commentary
This T+3 follow-up moved the name from unsupported to evidence-backed, but not to high conviction. Primary company materials confirmed a solid Q1 and reiterated outlook, while third-party post-print coverage still framed the reaction as cautious because EPS/loss quality and second-half dependence remain unresolved. We found limited broad analyst-revision evidence beyond a BTIG reiteration, so the clean read is still monitoring-style rather than a strong re-rating call.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-01eventJuly 1 CEO handoff is a real execution checkpoint for a still-unproven scale storyHigh impact
Ross Muken is scheduled to become CEO on July 1, 2026, with founder Jurgi Camblong transitioning to Executive Chairman subject to the June AGM; because SOPHiA is still balancing growth, margin improvement, and commercialization ramp, the leadership handoff could materially affect investor confidence in go-to-market execution and capital discipline [#PR-2026-01-12].
2026-09-30catalystQ1 beat plus reaffirmed 2026 guide now has to convert into back-half revenue rampHigh impact
Q1 revenue rose 22% to $21.7 million, net dollar retention reached 117%, and management reaffirmed 2026 revenue guidance of $92 million-$94 million while saying 18 new core genomic customers signed in Q1 should begin generating revenue over the next twelve months; the near-term test is whether those wins and prior large U.S. health-system signings translate into the expected second-half ramp rather than staying stuck in implementation [#6K-2026-05-05] [#6K-2026-03-03].
2026-12-31catalystLiquid biopsy, solid tumor, and BioPharma ramps still offer upside if implementations keep convertingHigh impact
SOPHiA exited 2025 with over 70 liquid-biopsy customers signed and 21 solid-tumor customers signed, then said in Q1 2026 it had reached 100 customers across 30-plus countries signed to adopt liquid-biopsy or solid-tumor applications while liquid-biopsy analyses grew more than 100% year over year; that creates a credible multi-quarter activation tail, but the value still depends on implementation speed and routine-usage conversion [#6K-2026-03-03] [#6K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology